The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients (Pts).
M. Y. Al-Marrawi
No relevant relationships to disclose
B. I. Rini
Consultant or Advisory Role - AVEO; GlaxoSmithKline; Pfizer
Research Funding - GlaxoSmithKline; Pfizer
L. C. Harshman
Consultant or Advisory Role - Novartis
Research Funding - Genentech; Novartis
G. A. Bjarnason
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Research Funding - Pfizer
L. Wood
No relevant relationships to disclose
U. N. Vaishampayan
Honoraria - GlaxoSmithKline; Novartis; Pfizer
Research Funding - GlaxoSmithKline; Novartis; Pfizer
M. J. MacKenzie
No relevant relationships to disclose
J. J. Knox
Research Funding - Bayer; Novartis; Pfizer
N. Agarwal
No relevant relationships to disclose
C. K. Kollmannsberger
No relevant relationships to disclose
M. Tan
No relevant relationships to disclose
S. Y. Rha
No relevant relationships to disclose
F. Donskov
No relevant relationships to disclose
S. A. North
No relevant relationships to disclose
T. K. Choueiri
No relevant relationships to disclose
D. Y. C. Heng
No relevant relationships to disclose